dostęp otwarty

Tom 19, Nr 3 (2015)
ORIGINAL PAPERS
Opublikowany online: 2015-09-29
Pobierz cytowanie

Treatment with cinacalcet decreases systolic blood pressure in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism

Piotr Kuczera, Marcin Adamczak, Andrzej Wiecek
DOI: 10.5603/AH.2015.0016
·
Arterial Hypertension 2015;19(3):129-134.

dostęp otwarty

Tom 19, Nr 3 (2015)
ORIGINAL PAPERS
Opublikowany online: 2015-09-29

Streszczenie

Background There are numerous evidences suggesting that parathyroid hormone (PTH) plays a role in the pathogenesis of arterial hypertension. Treatment with cinacalcet decreases serum PTH concentration in haemodialysed patients with chronic kidney disease (HDP) and secondary hyperparathyroidism (sHPT) Chronic kidney disease is a pro-inflammatory state. The aim of this study was therefore to assess the influence of 6-month treatment with cinacalcet on blood pressure (BP) and inflammation markers in HDP with sHPT.

Material and methods In 58 HDP with sHPT serum PTH, interleukin-6, C-reactive protein, calcium and phosphate concentrations were assessed before the first dose of cinacalcet and after 3 and 6 months of treatment. BP was measured before haemodialysis sessions.

Results Serum PTH concentration decreased significantly after 3 and 6 months of cinacalcet treatment from 1138 (931–1345) to 772 (551–992); p < 0.0001 and to 635 (430–839) pg/ml; p < 0.0001, respectively. Systolic BP decreased after 3 and 6 months of treatment from 128 (123–133), to 125 (120–131) and to 121 (115–127) mm Hg, respectively (p for trend = 0.014). Diastolic BP did not change significantly. There were no significant differences in the number of antihypertensive drugs, vitamin D analogues dose and patients’ body weight, nor the serum concentrations of IL-6 and CRP during the treatment period.

Conclusions 1. Six-month treatment with cinacalcet decreases systolic BP in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. 2. The elucidation of exact pathomechanism of such a BP decrease needs further clinical studies, but it seems not to be related to inflammatory status changes.

Streszczenie

Background There are numerous evidences suggesting that parathyroid hormone (PTH) plays a role in the pathogenesis of arterial hypertension. Treatment with cinacalcet decreases serum PTH concentration in haemodialysed patients with chronic kidney disease (HDP) and secondary hyperparathyroidism (sHPT) Chronic kidney disease is a pro-inflammatory state. The aim of this study was therefore to assess the influence of 6-month treatment with cinacalcet on blood pressure (BP) and inflammation markers in HDP with sHPT.

Material and methods In 58 HDP with sHPT serum PTH, interleukin-6, C-reactive protein, calcium and phosphate concentrations were assessed before the first dose of cinacalcet and after 3 and 6 months of treatment. BP was measured before haemodialysis sessions.

Results Serum PTH concentration decreased significantly after 3 and 6 months of cinacalcet treatment from 1138 (931–1345) to 772 (551–992); p < 0.0001 and to 635 (430–839) pg/ml; p < 0.0001, respectively. Systolic BP decreased after 3 and 6 months of treatment from 128 (123–133), to 125 (120–131) and to 121 (115–127) mm Hg, respectively (p for trend = 0.014). Diastolic BP did not change significantly. There were no significant differences in the number of antihypertensive drugs, vitamin D analogues dose and patients’ body weight, nor the serum concentrations of IL-6 and CRP during the treatment period.

Conclusions 1. Six-month treatment with cinacalcet decreases systolic BP in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. 2. The elucidation of exact pathomechanism of such a BP decrease needs further clinical studies, but it seems not to be related to inflammatory status changes.

Pobierz cytowanie

Słowa kluczowe

chronic kidney disease, secondary hyperparathyroidism, cinacalcet, blood pressure, haemodialysis

Informacje o artykule
Tytuł

Treatment with cinacalcet decreases systolic blood pressure in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism

Czasopismo

Arterial Hypertension

Numer

Tom 19, Nr 3 (2015)

Strony

129-134

Data publikacji on-line

2015-09-29

DOI

10.5603/AH.2015.0016

Rekord bibliograficzny

Arterial Hypertension 2015;19(3):129-134.

Słowa kluczowe

chronic kidney disease
secondary hyperparathyroidism
cinacalcet
blood pressure
haemodialysis

Autorzy

Piotr Kuczera
Marcin Adamczak
Andrzej Wiecek

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Czasopismo Nadciśnienie Tętnicze dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl